Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMTY169)

Drug Name
Norethindrone Drug Info
Synonyms
Activella; Anhydrohydroxynorprogesterone; Anovulatorio; Anovule; Brevicon; Brevinor; Camila; Ciclovulan; Conceplan;Conludaf; Conludag; Demulen; Errin; Estrinor; Ethinylnortestosterone; Ethynylmortestosterone; Ethynylnortestosterone; Gencept; Genora; Gestest; Jenest; Loestrin; Menzol; Microneth; Micronett; Micronor; Micronovum; Milli; Minovlar; Nelova; Nodiol; Noraethisteronum; Noralutin; Norcept; Norcolut; Norcolute; Noresthisterone; Norethadrone; Norethin; Norethindirone; Norethisteron; Norethisterone; Norethisteronum; Norethyndron; Norethynodron; Norethynodrone; Noretisterona; Noretisterone; Norfor; Norgestin; Noriday; Norluten; Norlutin; Norluton; Normapause; Norpregneninlone; Norpregneninolone; Norpregneninotone; Orlest; Proluteasi; Synphase; Triella; Utovlan; Utovlar; Component of Noriday; Norethindrone Norethisterone; Norethindrone [USAN]; Norethisterone [Progestins]; Noretisterone [DCIT]; Primolut N; Brevinor 21; Brevinor 28; Noriday 28; Ortho 1 35; Ortho 7 7 7; Ovysmen 1 35; SC 4640; Synphasic 28; Trinovum 21; Brevinor-1 21; Brevinor-1 28; Camila (TN); Jenest-28; Micronor (TN); Mini-Pe; Mini-pill; Nor-QD; Nora-BE; Norcept-E; Norethin 1/35 E; Norethin 1/50 M; Norethindrone (USP); Norethisterone (JP15); Norethisteronum [INN-Latin]; Noretisterona [INN-Spanish]; Ortho-Novum 1 35; Ortho-Novum 1 50; Ortho-Novum 7 7 7; Ovysmen 0.5 35; Primolut-N; Tri-Norinyl; Ethinyl-19-nortestosterone; Nor-Q.D; Primolut-N (TN); Nor-Q.D.; 17-Ethinyl-19-nortestosterone; 17-Ethynyl-17-hydroxyestr-4-en-3-one; 17-alpha-Ethynyl-19-nortestosterone; 17-alpha-Ethynyl-4-estren-17-ol-3-one; 17-ethynyl-17beta-hydroxyestr-4-en-3-one; 17.alpha.-Ethinyl-19-nortestosterone; 17.alpha.-Ethynyl-19-nortestosterone; 17.alpha.-Ethynyl-4-estren-17-ol-3-one; 17alpha-Ethinyl-19-nortestosterone; 17alpha-Ethynyl-19-nortestosterone; 17alpha-Ethynyl-4-estren-17-ol-3-one; 19-Nor-17-alpha-ethynyltestosterone; 19-Nor-17-ethinyltestosterone; 19-Nor-17.alpha.-ethynyltestosterone; 19-Nor-17alpa-ethynyltestosterone; 19-Nor-17alpha-ethynyltestosterone; 19-Nor-ethindrone; 19-Nor-ethinyl-4,5-testosterone; 19-Norethindrone; 19-Norethinyltestosterone; 19-Norethisterone; 4-Estren-17alpha-ethynyl-17beta-ol-3-one
Therapeutic ClassContraceptive Agents
Cross-matching ID
PubChem CID
6230
ChEBI ID
CHEMBL1162
CAS Number
CAS 68-22-4
TTD Drug ID
D0GL7U
ACDINA Drug ID
D00478

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Proteasome 2.19 0.00e+0 44/46 (95.65%) PSMD2;PSMC2;PSMD3;...
Oxidative phosphorylation 1.95 6.20e-3 93/133 (69.92%) ATP5MF;COX17;ATP5MC1;...
Protein export 1.90 8.27e-3 17/23 (73.91%) HSPA5;SEC61A1;SEC61G;...
NF-kappa B signaling pathway -1.67 4.75e-2 90/104 (86.54%) NFKB1;ICAM1;RELB;...
Fat digestion and absorption -1.67 4.92e-2 35/43 (81.4%) PLPP2;ABCA1;DGAT1;...
Central carbon metabolism in cancer -1.69 4.54e-2 67/70 (95.71%) PFKM;GLS2;PIK3CA;...
Human cytomegalovirus infection -1.71 4.20e-2 201/225 (89.33%) CYCS;TSC1;CDKN1A;...
Osteoclast differentiation -1.71 4.31e-2 117/127 (92.13%) LCP2;MAPK14;TNFSF11;...
Coronavirus disease -1.73 3.74e-2 215/232 (92.67%) RPL4;CXCL10;TYK2;...
Herpes simplex virus 1 infection -1.74 3.64e-2 165/498 (33.13%) ITGB3;BID;IL1B;...
Circadian entrainment -1.74 3.83e-2 85/97 (87.63%) PRKACA;GNB5;GNG5;...
Inflammatory bowel disease -1.76 3.72e-2 58/65 (89.23%) RELA;SMAD2;IL18RAP;...
Inflammatory mediator regulation of TRP channels -1.77 3.94e-2 82/98 (83.67%) PLCB4;F2RL1;ADCY2;...
Amoebiasis -1.79 3.70e-2 99/102 (97.06%) COL1A1;IL1B;SERPINB10;...
TNF signaling pathway -1.79 4.11e-2 103/112 (91.96%) IL1B;TNFAIP3;TRAF3;...
Gastric acid secretion -1.80 3.99e-2 63/76 (82.89%) ITPR3;CAMK2G;KCNQ1;...
Dilated cardiomyopathy -1.80 4.37e-2 86/96 (89.58%) TPM4;ACTC1;ITGA8;...
Human T-cell leukemia virus 1 infection -1.82 4.46e-2 197/219 (89.95%) TCF3;TNFRSF1A;CDK2;...
Amphetamine addiction -1.84 4.85e-2 57/69 (82.61%) GRIA1;CAMK2G;PPP3CB;...
Rheumatoid arthritis -1.89 3.83e-2 78/93 (83.87%) LTB;CSF2;CSF1;...
Th1 and Th2 cell differentiation -1.91 3.40e-2 80/92 (86.96%) TYK2;MAML1;JAG2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H